CN102188598B - Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus - Google Patents
Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus Download PDFInfo
- Publication number
- CN102188598B CN102188598B CN 201110118074 CN201110118074A CN102188598B CN 102188598 B CN102188598 B CN 102188598B CN 201110118074 CN201110118074 CN 201110118074 CN 201110118074 A CN201110118074 A CN 201110118074A CN 102188598 B CN102188598 B CN 102188598B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine
- lamivudine
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicine formula for improving the response of lamivudine in resisting hepatitis B virus. The Chinese medicine is prepared from the following raw materials by weight of parts: 10 to 15 parts of Radix Astragali, 10 to 15 parts of sophora flavescens and 10 parts of anemarrhena. The invention also discloses the preparation method and application of the above-mentioned traditional Chinese medicine formula. The Chinese medicine formula provided in the invention is characterized by clear medicine components and dosage, strong objectivity, clear curative effect, strong objective clinic evidence, good medicine compatibility, sweet flavor, mild property, no stimulation to alimentary canal or toxic side effects to liver or kidney and good survivability for a long-term treatment. Besides, the steps of decocting medicine components and taking medicine are clear, so it is easy for a patient to use; the medicine is clinic and commonly used, so it is convenient to draw materials; the formula components are common herb medicines, so the prices are not steep.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field, be specifically related to a kind of Chinese medicine preparation that the treatment of lamivudine anti-hepatitis virus is replied that improves.
Background technology
According to World Health Organization (WHO), about 2,000,000,000 people in the whole world once infected hepatitis B virus (HBV), and wherein 3.5 hundred million people be the chronic HBV infection person, and annual have 1,000,000 people to die from liver failure, liver cirrhosis and hepatocarcinoma due to the HBV infection approximately.National hepatitis B Epidemiological study in 2006 shows that China's general crowd HBsAg carrying rate is 7.18%, about 9,300 ten thousand people of the existing chronic HBV infection person of China, wherein about 2,000 ten thousand examples of chronic hepatitis B patient.Chronic viral hepatitis B becomes commonly encountered diseases, the frequently-occurring disease that has a strong impact on national health.
Chronic hepatitis B treatment mainly comprises antiviral, immunomodulating, antiinflammatory and antioxidation, fibrosis and symptomatic treatment, and wherein antiviral therapy is crucial, as long as indication is arranged, and conditions permit, just should carry out the antiviral therapy of standard.Antiviral drugs comprises two types of interferon (IFN) and nucleoside medicines.Interferon comprises IFN α (2a, 2b and 1b) and glycol interferon alpha (2a and 2b) [PegIFN α (2a and 2b)]; Nucleoside medicine comprises lamivudine, adefovir ester, Entecavir and Sebivo.
The negative chronic hepatitis B patient of common interferon (IFN) treatment HBeAg, lasting response rate is merely 10%～47% (average 24%).Can produce influenza appearance syndrome, the property crossed a PBC minimizing, psychological problem in the interferon therapy, bring out untoward reaction such as autoimmune disease, kidney damage, cardiovascular complication, retinopathy, auditory dysesthesia and interstitial pneumonia.Interferon therapy has absolute contraindications such as gestation, psychiatric history, the epilepsy of failing to control, the excessive drinking of not giving up or junkie, the autoimmune disease without control, mistake compensatory liver cirrhosis, Symptomatic heart disease, and clinical application receives certain limitation.
Lamivudine can obviously suppress the HBV dna level, but the complete response rate of antiviral therapy is low: HBeAg serology conversion ratio is respectively 16%, 17%, 23%, 28% and 35% in treatment in the time of 1,2,3,4 and 5 year.For reaching higher complete response rate, need long-term prescription, with the treatment time prolongation, the incidence rate of viral medicament-resistant mutation increases (being respectively 14%, 38%, 49% and 66% on the 1st, 2,3,4 year).The virus medicament-resistant mutation causes the state of an illness to occur repeatedly even increases the weight of to cause death.Therefore, improve anti-hepatitis virus treatment response rate, become clinical key issue.
Summary of the invention
Technical problem to be solved by this invention provides a kind of lamivudine anti-hepatitis virus that can significantly improve and treats the Chinese medicine preparation of replying.
The technical problem that the present invention also will solve provides the method for preparing of above-mentioned Chinese medicine preparation.
The technical problem that the present invention will solve at last provides the application of above-mentioned Chinese medicine preparation.
For solving the problems of the technologies described above, the technical scheme that the present invention adopts is following:
A kind of lamivudine anti-hepatitis virus that improves is treated the Chinese medicine preparation of replying, and it is obtained by the feedstock production of following parts by weight: 10～15 parts of the Radixs Astragali, 10～15 parts of Radix Sophorae Flavescentiss, 10 parts of the Rhizoma Anemarrhenaes.
The method for preparing of above-mentioned Chinese medicine preparation, with 10～15 parts of the Radixs Astragali, 10～15 parts of Radix Sophorae Flavescentiss, 10 parts of mixing of the Rhizoma Anemarrhenae, collecting decoction is filtered in decocte with water 2～3 times.
Above-mentioned Chinese medicine preparation improves the treatment of lamivudine anti-hepatitis virus in preparation and replys the application in the medicine.
The Radix Astragali; Nature and flavor are sweet, warm, and " book on Chinese herbal medicine converges and says " called its " arresting sweating is defended in tonifying the lung spleen invigorating in fact; wind dispelling fortune poison "; Materia Medica of Decoction meaning its " tonifying five ZANG-organs is all empty not enough ", experimentation confirm that astragalus polysaccharides and astragaloside can make IFN-(IFN-γ) thereby, the concentration of interleukin-1 ' beta ' raises and makes macrophage activation, phagocytic activity strengthens; Radix Astragali injection acupoint injection therapy treatment chronic viral hepatitis B, the HBsAg titre descends obviously, and negative conversion rate is 45.4%.Radix Sophorae Flavescentis, bitter, cold, " herbal classic " called its " the depressed ， lumps in the chest and abdomen of main trusted subordinate, jaundice ", and oxymatrine can suppress the HepG2.2.15 emiocytosis HBsAg and the HBeAg of hepatitis B virus DNA transfection; Matrine can significantly alleviate hepatocellular degeneration necrosis and proliferation of fibrous tissue, reduces serum alanine aminotransferase, hyaluronic acid, hepatic tissue hydroxyproline content, has effect of anti hepatic fibrosis.The Rhizoma Anemarrhenae, bitter, cold, effect clearing away heat-fire, nourshing Yin and drynsessmoistening prescription, " book on Chinese herbal medicine converges and says " called its " medicine of YIN nourishing Ji water ".
The property of Radix Astragali temperature compensation gets the cold and unlikely too hot dry of Radix Sophorae Flavescentis, the Rhizoma Anemarrhenae; The property that the Rhizoma Anemarrhenae is moisturized gets temperature and the fraud of unlikely impairment of YANG laxation of the Radix Astragali; The Radix Sophorae Flavescentis compatibility Rhizoma Anemarrhenae has the effect of growing lung kidney, liver heat removing stomach, and the power of detoxifcation is stronger; Three medicine compatibilities mend mutually 5 clearly, cold temperature develops simultaneously, the sweetness and bitterness mutual aid, and temperature and not dry, profit and cold have the effect of setting upright QI invigorating, spleen invigorating easing the affected liver, removing liver heat and toxic substances.
The Radix Astragali, the Rhizoma Anemarrhenae, Radix Sophorae Flavescentis three medicine compatibilities, the patient of the male chronic viral hepatitis B syndrome of dampness-heat due to spleen deficiency of associating lamivudine therapy HBeAg through herbs intervention, improves hepatitis B virus converting negative rate, HBeAg negative conversion rate, HBeAg serology conversion ratio and ALT normalization rate.
Beneficial effect: Chinese medicine preparation of the present invention, medicine composition and dosage are clear and definite, and objectivity is strong; The prescription curative effect is clear and definite, and clinical evidence is objective strong; Compatibility of drugs sweet in the mouth, property are gentle, and no digestive tract stimulates and the Liver and kidney toxicity, takes better tolerance for a long time; It is clear and definite that prescription drug decocts the program of taking, and is easy to the patient and grasps use; Medicine is a clinical commonly used drug, the facility of drawing materials; The prescription medical material is draft class common drug, low price.
The specific embodiment
According to following embodiment, can understand the present invention better.Yet, those skilled in the art will readily understand that the described content of embodiment only is used to explain the present invention, and the present invention that should also can not limit in claims to be described in detail.
Embodiment 1:
Get the crude drug decoction pieces: Radix Astragali 10-15g, Radix Sophorae Flavescentis 10-15g, Rhizoma Anemarrhenae 10g mixes, and decocte with water 2 times is filtered, and the common 400ml that must filtrate divides 2 times decoction being taken warmly sooner or later, each 200ml.
Embodiment 2:
The chronic viral hepatitis B patient pathogenesis of lamivudine antiviral therapy is to accumulate in liver spleen kidney deficiency, the damp and hot blood stasis, and common Syndrome in TCM marquis is insufficiency of the spleen, damp and hot, stagnation of liver-QI etc.According to clinical card marquis result of study, and, set up the compatible combination of the Radix Astragali, the Rhizoma Anemarrhenae, Radix Sophorae Flavescentis according to practical experience.
Medicine soup so that embodiment 1 makes is united lamivudine therapy HBeAg positive chronic hepatitis B.
Method: 59 routine chronic viral hepatitis B patients are divided into 2 groups at random; The medicine soup associating lamivudine therapy that 30 examples make with embodiment 1 is organized in treatment; Matched group 29 examples in 52 weeks of the course of treatment, are observed the variation of treatment front and back serum hepatitis B virus carrying capacity, hepatitis B mark, liver function with lamivudine therapy.
Result:, see table 1 through the treatment in 52 weeks.
Table 1
| The treatment group | Matched group | |
| The hepatitis B virus converting negative rate | 93.33％* | 72.41％* |
| The HBeAg negative conversion rate | 46.67％* | 20.69％* |
| HBeAg serology conversion ratio | 33.33％** | 17.24％** |
| The ALT normalization rate | 96.66％* | 79.31％* |
*P＜0.05，**P＝0.16
The medicine soup associating lamivudine therapy HBeAg positive chronic hepatitis B that conclusion: embodiment 1 makes can improve antiviral response.
Claims (3)
1. one kind is improved the Chinese medicine compound that the treatment of lamivudine anti-hepatitis virus is replied, and it is characterized in that it is obtained by the feedstock production of following parts by weight: 10～15 parts of the Radixs Astragali, 10～15 parts of Radix Sophorae Flavescentiss, 10 parts of the Rhizoma Anemarrhenaes.
2. the described raising lamivudine of claim 1 anti-hepatitis virus is treated the method for preparing of the Chinese medicine compound of replying, and it is characterized in that, with 10～15 parts of the Radixs Astragali, 10～15 parts of Radix Sophorae Flavescentiss, 10 parts of mixing of the Rhizoma Anemarrhenae, collecting decoction is filtered in decocte with water 2～3 times.
3. the described raising lamivudine of claim 1 anti-hepatitis virus is treated the Chinese medicine compound of replying and is replied the application in the medicine in the treatment of preparation raising lamivudine anti-hepatitis virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110118074 CN102188598B (en) | 2011-05-09 | 2011-05-09 | Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110118074 CN102188598B (en) | 2011-05-09 | 2011-05-09 | Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102188598A CN102188598A (en) | 2011-09-21 |
| CN102188598B true CN102188598B (en) | 2012-08-22 |
Family
ID=44598033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110118074 Expired - Fee Related CN102188598B (en) | 2011-05-09 | 2011-05-09 | Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102188598B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016096800A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Biomarkers for hbv treatment response |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686388A (en) * | 2005-04-11 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
| CN1977886B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus |
| CN1977889B (en) * | 2005-12-05 | 2012-03-21 | 山东轩竹医药科技有限公司 | Medicinal composition of astragalus, salvia miltrorrhiza and oxymatrine, and its preparing method |
-
2011
- 2011-05-09 CN CN 201110118074 patent/CN102188598B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686388A (en) * | 2005-04-11 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
| CN1977886B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus |
| CN1977889B (en) * | 2005-12-05 | 2012-03-21 | 山东轩竹医药科技有限公司 | Medicinal composition of astragalus, salvia miltrorrhiza and oxymatrine, and its preparing method |
Non-Patent Citations (3)
| Title |
|---|
| 吕明磊等.苦参素与黄芪注射液联合治疗慢性乙肝疗效观察.《临床心身疾病杂志》.2005,第11卷(第03期), * |
| 唐光钰.乙肝拮抗丸治疗慢性乙型肝炎42例.《新中医》.1994,(第10期), * |
| 蔡林光.黄芪在急性黄疸型肝炎治疗中的应用.《新中医》.1994,(第07期), * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016096800A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Biomarkers for hbv treatment response |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102188598A (en) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940830B (en) | Ointment for tonifying lungs and relieving coughs | |
| CN102755594A (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN111214566A (en) | Epidemic prevention traditional Chinese medicine composition and preparation method and application thereof | |
| CN102631610B (en) | Chinese herb for treating pediatric chronic cough | |
| CN104042802A (en) | Traditional Chinese medicine composition capable of treating fatty liver | |
| CN102380061A (en) | Chinese medicinal composition for eliminating and dissolving phlegm and relieving cough, as well as preparation method and application thereof | |
| CN100400094C (en) | Traditional Chinese medicine for treating hepatitis B and its preparing process | |
| CN104707108A (en) | Traditional Chinese medicine composition for treating chronic virulent hepatitis b and preparation method thereof | |
| CN101361946A (en) | Traditional Chinese medicine combination for treating hepatitis B | |
| CN102188598B (en) | Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus | |
| CN102552631A (en) | Chinese herbal preparation having protective effect on alcoholic hepatic injury | |
| CN102988832B (en) | Traditional Chinese medicine composition used for treating asthma of children | |
| CN105288494A (en) | Tea for curing hepatitis B | |
| CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| CN102068585B (en) | Chinese medicinal compound preparation for treating chronic nephritis and nephrotic syndromes | |
| CN101011457A (en) | Traditional Chinese medicine composition with immunological enhancement function | |
| CN102228593B (en) | Chinese herbal medicine prescription for treating esophagus cancer, and preparation method thereof | |
| CN102188499B (en) | Ganoderma liver-protection tea and preparation method thereof | |
| CN110575521A (en) | Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application | |
| CN108785575A (en) | A kind of Chinese herbal ointment formula | |
| CN103007204A (en) | Chinese medicinal composition for treating hepatofibrosis | |
| CN102846965A (en) | Traditional Chinese medicine preparation capable of resisting HIV and improving immunity and preparation method of traditional Chinese medicine | |
| CN102935183B (en) | Children virus pneumonia treatment decoction | |
| CN108653546A (en) | A kind of Chinese medicine preparation improving lamivudine in resisting hepatitis B virus response | |
| CN116059281A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or treating viral hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 Termination date: 20140509 |